Top London Biotech Companies (137)
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation
At Eucalyptus, we run a trusted group of digital healthcare clinics on our telehealth platform including Pilot (men’s health), Kin (fertility), Software (dermatology) and Juniper (weight loss and menopause). Our mission is to bring high-touch, high-quality healthcare to patients around the world by empowering practitioners with technology. Since 2019, we’ve facilitated over one million consultations across Australia, the UK and Germany. With every consult, we’re breaking down boundaries to better health by providing better access to care, stigma-free experiences, and continuous support. Our commitment to providing better patient experiences is matched by our stellar record of patient safety. To learn more about Eucalyptus, visit our website
At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.
We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.
The Crick is a distinctive biomedical research institute. We’re committed to advancing, promoting, and sharing understanding of human health and disease. We do that by attracting talented and ambitious people from all disciplines and backgrounds and giving them the support and freedom they need to succeed. Inside the Crick, you’ll discover scientists working to stretch the very limits of what we know about how life works. Their research holds the key to answering fundamental questions about human health and disease. Our bold and innovative research projects bring together scientists and technicians from all disciplines in the pursuit of discovery without boundaries. With the support of our partners, we’re bridging the gap between discovery and application to help change lives for the better. And through our dynamic structure, we’re able to develop the science leaders of tomorrow. That’s our bold idea, tell us yours. Cover image taken at the Crick by Thomas Angus, Imperial College London
The AI Neuroscience Company. Currently in stealth mode.
EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way.
FlexSEA is a sustainable-packaging company aiming to replace traditional petroleum plastic film with an innovative natural material derived from seaweed. Our transparent, resistant material is degradable in marine, soil and home-composting environments and is also edible. We want to redefine the way people see plastic packaging. We want to innovate and change the way we see and use plastics. At FlexSea we believe the packaging of the future to be a packaging that is born in nature, serves its purpose, and returns to nature in a harmless way. A packaging that is built to exist, protect and preserve its contents only for the duration that these exist for. At FlexSea the future is now
LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA™). Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology and robotics.
Based in London, Hoxton Farms is creating a deliciously fatty future. We craft cruelty-free, sustainable fats to combine with plant protein for delicious meat alternatives
Our discovery platform uniquely combines target quantum mapping and AI led chemistry to enable faster development of better drug candidates. Our unique approach tackles common challenges in both AI driven drug design and target driven drug discovery. Quantum Mapping of targets introduces selectivity from the start, producing superior candidates in fewer design rounds. Identifying better starting points for AI-led chemistry eliminates bottlenecks in the hit to candidate optimization phase. Generating better Enzyme Inhibitors by targeting Quantum Transition States. We work with enzyme inhibitors in a unique way, continually developing tools to address the challenges of working with machine learning and quantum simulations in drug discovery. This strategy significantly improves the quality of new drugs being produced, as well as reduces discovery time. Our advisors and partners include leading academics and providers in the fields of quantum computing, AI and machine learning and drug discovery. In addition to our in-house discovery programs, we are interested in drug discovery collaborations with pharmaceutical and biotech companies seeking new approaches to novel, first in class, best in class or next generation inhibitors for validated or intractable enzyme targets.
UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 8500 employees in approximately 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2021 Key Financials: €5.8 billion global revenue Specialties: Neurology, Immunology
Hidden within our planet's vast biodiversity are solutions to some of humanity's greatest challenges, with the potential to deliver sustainable food supplies, revolutionary manufacturing capabilities, and a new generation of medicines. At Basecamp Research, we are building BaseDiscovery, a platform technology that will use next-gen DNA analysis and environmental monitoring to connect the dots and improve our understanding of the natural world. Our team uses a unique and fully portable laboratory capable of rapidly analysing nature anywhere on Earth, discovering novel solutions to the world's most pressing challenges
SIME is a clinical AI company applying medical excellence, proprietary AI and data ingenuity to deliver rapid respiratory intensive care diagnostics for acute unmet needs. Our clinically proven technology enables early intervention in life-threatening diseases - improving outcomes and reducing costs.
We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
Work Your Passion. Live Your Purpose.
Industry
Work Your Passion. Live Your Purpose.
